| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.25260 |
| P698 | PubMed publication ID | 23115047 |
| P2093 | author name string | Todd B Sherer | |
| Deborah W Brooks | |||
| Sohini Chowdhury | |||
| Katherine Peabody | |||
| P2860 | cites work | Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues | Q22253049 |
| Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism | Q24321359 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Q24634577 | ||
| Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease | Q28192834 | ||
| The price of innovation: new estimates of drug development costs | Q28212140 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| The Parkinson's complex: parkinsonism is just the tip of the iceberg | Q28303954 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. | Q30419918 | ||
| The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. | Q30458705 | ||
| Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs | Q30810700 | ||
| Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra | Q33658913 | ||
| Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease | Q33723751 | ||
| Limitations of current Parkinson's disease therapy | Q34187123 | ||
| Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity | Q34201593 | ||
| The Parkinson Progression Marker Initiative (PPMI). | Q34217468 | ||
| A double-blind, delayed-start trial of rasagiline in Parkinson's disease | Q34612128 | ||
| LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice | Q35288337 | ||
| Assessing research participants' perceptions of their clinical research experiences | Q36808362 | ||
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
| Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model | Q37289669 | ||
| Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations | Q37716740 | ||
| Defining disease‐modifying therapies for PD—A road map for moving forward | Q37788638 | ||
| Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. | Q39665353 | ||
| What motivates Parkinson's disease patients to enter clinical trials? | Q39734117 | ||
| Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial | Q42751053 | ||
| Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. | Q45981005 | ||
| Recruitment for controlled clinical trials: literature summary and annotated bibliography. | Q49109414 | ||
| Smoking and Parkinson's disease: a dose-response relationship. | Q50537929 | ||
| Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. | Q54781213 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 1606-1611 | |
| P577 | publication date | 2012-10-31 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Overcoming obstacles in Parkinson's disease | |
| P478 | volume | 27 |
| Q39264615 | Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA. |
| Q26995786 | Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments |
| Q64778733 | NADPH Oxidase Mediates Membrane Androgen Receptor-Induced Neurodegeneration. |
| Q47171349 | Neuroprotection of Granulocyte Colony-Stimulating Factor for Early Stage Parkinson's Disease |
| Q38079790 | Obstacles to the development of a neuroprotective therapy for Parkinson's disease |
| Q47165927 | Parkinson's disease and atypical parkinsonism: the importance of magnetic resonance imaging as a potential biomarker |
| Q92354306 | Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World |
| Q49601287 | Sex-related differences in oxidative stress and neurodegeneration. |
| Q38275171 | The ongoing pursuit of neuroprotective therapies in Parkinson disease |
| Q38137889 | Therapeutic prospects for Parkinson disease |
| Q41429938 | Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neurons |
Search more.